

TIVAPRAMIDE
(Loperamide Capsules BP 2 mg)

1.3.1.2 Qualitative and quantitative composition:

Each Capsule Contains:

Loperamide Hydrochloride BP 2 mg

Excipients Q.S.

Approved Colour Used in Empty Capsule Shell.

Sr. No.	Ingredients	Specification	Label Claim / Capsule (In mg)	Over-ages added (In %)	Qty. / Capsule (In mg)	Reason for Inclusion
1.	Loperamide hydrochloride*	BP	2.00	2 %	2.040	Medicament
2.	Sodium starch glycolate	BP	NA	NA	14.00	Disintegrant
3.	Microcrystalline cellulose	BP	NA	NA	55.25	Diluent
4.	Colloidal anhydrous silica	BP	NA	NA	2.75	Glidant
5.	Lactose monohydrate (Dried)	BP	NA	NA	115.21	Diluent
6.	Magnesium stearate	BP	NA	NA	0.75	Lubricant
7.	EHG Capsule Size '2' Cap - Gray Body- Green	In-House	NA	NA	1 Capsule = 63 mg	Capsule Shell
	Net Content/Capsule (In mg)				190.00	
	Weight of Empty Hard Gelatin Capsule Shell (In mg)				63.00	
	Average Weight of Filled Capsule (In mg)				253.00	

*2 % overages to be taken to compensate process loss during blending.

1.3.1.3 Pharmaceutical form: Hard Gelatin Capsules

Description: Gray coloured cap and Green coloured body of capsule size 2 containing white powder.

1.3.1.4 Clinical Particulars

1.3.1.4.1 Therapeutic indications:

For the symptomatic treatment of acute diarrhoea, in adults and children 12 years and over. For the symptomatic treatment of acute episodes of diarrhoea associated with Irritable Bowel Syndrome in adults aged 18 years and over following initial diagnosis by a doctor.

1.3.1.4.2 Posology and method of administration

Posology:

Acute diarrhoea

Adults and children over 12:

2 capsules (4 mg) initially, followed by 1 capsule (2mg) after every loose stool.

The usual dose is 3-4 capsules (6 mg – 8 mg) a day. The total daily dose should not exceed 6 capsules (12 mg).

Symptomatic treatment of acute episodes of diarrhoea associated with irritable bowel syndrome in adults aged 18 and over

Two capsules (4 mg) to be taken initially, followed by 1 capsule (2mg) after every loose stool, or as previously advised by your doctor. The maximum daily dose should not exceed 6 capsules (12mg).

Paediatric population

Loperamide hydrochloride is contraindicated in children less than 12 years of age.

Elderly

No dose adjustment is required for the elderly.

Renal Impairment

No dose adjustment is required for patients with renal impairment.

Hepatic Impairment

Although no pharmacokinetic data are available in patients with hepatic impairment, loperamide hydrochloride should be used with caution in such patients because of reduced first pass metabolism.

Method of administration

Oral use. The capsules should be taken with liquid.

1.3.1.4.3 Contraindications

TIVAPRAMIDE (Loperamide Capsules BP 2mg) are contraindicated in:

- in patients with hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- in children less than 12 years of age.
- in patients with acute dysentery, which is characterised by blood in stools and high fever.
- in patients with acute ulcerative colitis.
- in patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella and Campylobacter.
- in patients with pseudomembranous colitis associated with the use of broad-spectrum antibiotics.

Loperamide hydrochloride must not be used when inhibition of peristalsis is to be avoided due to the possible risk of significant sequelae including ileus, megacolon and toxic megacolon. Loperamide hydrochloride must be discontinued promptly when ileus, constipation or abdominal distension develop.

1.3.1.4.4 Special warnings and precautions for use

Treatment of diarrhoea with loperamide hydrochloride is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate. The priority in acute diarrhoea is the prevention or reversal of fluid and electrolyte depletion. This is particularly important in young children and in frail and elderly patients with acute diarrhoea. Use of this medicine does not preclude the administration of appropriate fluid and electrolyte replacement therapy.

Since persistent diarrhoea can be an indicator of potentially more serious conditions, this medicine should not be used for prolonged periods until the underlying cause of the diarrhoea has been investigated.

In acute diarrhoea, if clinical improvement is not observed within 48 hours, the administration of loperamide hydrochloride should be discontinued and patients should be advised to consult their doctor.

Patients with AIDS treated with this medicine for diarrhoea should have therapy stopped at the earliest signs of abdominal distension. There have been isolated reports of obstipation with an increased risk for toxic megacolon in AIDS patients with infectious colitis from both viral and bacterial pathogens treated with loperamide hydrochloride.

Although no pharmacokinetic data are available in patients with hepatic impairment, this medicine should be used with caution in such patients because of reduced first pass metabolism, as it may result in a relative overdose leading to CNS toxicity.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine because it contains lactose.

If patients are taking this medicine to control episodes of diarrhoea associated with Irritable Bowel Syndrome previously diagnosed by their doctor, and clinical improvement is not observed within 48 hours, the administration of loperamide HCl should be discontinued and they should consult with their doctor. Patients should also return to their doctor if the pattern of their symptoms changes or if the repeated episodes of diarrhoea continue for more than two weeks.

Cardiac events including QT interval and QRS complex prolongation, torsade de pointes have been reported in association with overdose. Some cases had a fatal outcome (see section 4.9). Overdose can unmask existing Brugada syndrome. Patients should not exceed the recommended dose and/or the recommended duration of treatment.

1.3.1.4.5 Interaction with other medicinal products and other forms of interaction

Non-clinical data have shown that loperamide is a P-glycoprotein substrate. Concomitant administration of loperamide (16 mg single dose) with quinidine or ritonavir, which are both P-glycoprotein inhibitors, resulted in a 2 to 3-fold increase in loperamide plasma levels. The clinical relevance of this pharmacokinetic interaction with P-glycoprotein inhibitors, when loperamide is given at recommended dosages is unknown.

The concomitant administration of loperamide (4 mg single dose) and itraconazole, an inhibitor of CYP3A4 and P-glycoprotein, resulted in a 3 to 4-fold increase in loperamide plasma concentrations. In the same study a CYP2C8 inhibitor, gemfibrozil, increased loperamide by approximately 2-fold. The combination of itraconazole and gemfibrozil resulted in a 4-fold increase in peak plasma levels of loperamide and a 13-fold increase in total plasma exposure. These increases were not associated with central nervous system (CNS) effects as measured by psychomotor tests (i.e., subjective drowsiness and the Digit Symbol Substitution Test).

The concomitant administration of loperamide (16 mg single dose) and ketoconazole, an inhibitor of CYP3A4 and P-glycoprotein, resulted in a 5-fold increase in loperamide plasma concentrations. This increase was not associated with increased pharmacodynamic effects as measured by pupillometry.

Concomitant treatment with oral desmopressin resulted in a 3-fold increase of desmopressin plasma concentrations, presumably due to slower gastrointestinal motility.

It is expected that drugs with similar pharmacological properties may potentiate loperamide's effect and that drugs that accelerate gastrointestinal transit may decrease its effect.

1.3.1.4.6 Pregnancy and Lactation

Pregnancy

Safety in human pregnancy has not been established, although from animal studies there are no indications that loperamide hydrochloride possesses any teratogenic or embryotoxic properties. As with other drugs, it is not advisable to administer this medicine in pregnancy, especially during the first trimester.

Lactation

Small amounts of loperamide may appear in human breast milk. Therefore, this medicine is not recommended during breast-feeding.

Women who are pregnant or breast feeding infants should therefore be advised to consult their doctor for appropriate treatment.

1.3.1.4.7 Effects on ability to drive and use machines

Loss of consciousness, depressed level of consciousness, tiredness, dizziness, or drowsiness may occur when diarrhoea is treated with this medicine. Therefore, it is advisable to use caution when driving a car or operating machinery.

1.3.1.4.8 Undesirable effects

Adults and children aged >12 years

The safety of loperamide hydrochloride was evaluated in 2755 adults and children aged ≥ 12 years who participated in 26 controlled and uncontrolled clinical trials of loperamide HCl used for the treatment of acute diarrhoea.

The most commonly reported (i.e., $\geq 1\%$ incidence) adverse drug reactions (ADRs) in clinical trials with loperamide hydrochloride in acute diarrhoea were: constipation (2.7%), flatulence (1.7%), headache (1.2%) and nausea (1.1%).

Table 1 displays ADRs that have been reported with the use of loperamide HCl from either clinical trial (acute diarrhoea) or post-marketing experience.

The frequency categories use the following convention: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); and very rare ($< 1/10,000$).

Table 1: Adverse Drug Reactions

System Organ Class	Indication		
	Common	Uncommon	Rare
Immune System Disorders			Hypersensitivity reaction Anaphylactic reaction (including Anaphylactic shock) Anaphylactoid reaction
Nervous System Disorders	Headache	Dizziness Somnolence	Loss of consciousness Stupor Depressed level of consciousness Hypertonia Coordination abnormality

Eye Disorders			Miosis
Gastrointestinal Disorders	Constipation Nausea Flatulence	Abdominal pain Abdominal discomfort Dry mouth Abdominal upper pain Vomiting Dyspepsia ^a	Ileus (including paralytic ileus) Megacolon (including toxic mega colon) Abdominal distension
Skin and Subcutaneous Tissue Disorders		Rash	Bullous eruption (including Stevens-Johnson syndrome, Toxic epidermal necrolysis and Erythema multiforme) Angioedema Urticaria Pruritus
Renal and Urinary Disorders			Urinary retention
General Disorders and Administration Site Conditions			Fatigue

Inclusion of this term is based on post-marketing reports for loperamide HCl. As the process for determining post marketing ADRs did not differentiate between chronic and acute indications or adults and children, the frequency is estimated from all clinical trials with loperamide HCl (acute and chronic), including trials in children ≤ 12 years (N=3683).

1.3.1.4.9 Overdose

Symptoms:

In case of overdose (including relative overdose due to hepatic dysfunction), CNS depression (stupor, coordination abnormality, somnolence, miosis, muscular hypertonia, and respiratory depression), constipation, urinary retention and ileus may occur. Children and patients with hepatic dysfunction, may be more sensitive to CNS effects.

In individuals who have ingested overdoses of loperamide HCl, cardiac events such as QT interval and QRS complex prolongation, torsade de pointes, other serious ventricular arrhythmias, cardiac arrest and syncope have been observed. Fatal cases have also been reported. Overdose can unmask existing Brugada syndrome.

Management:

If symptoms of overdose occur, naloxone can be given as an antidote. Since the duration of action of loperamide is longer than that of naloxone (1 to 3 hours), repeated treatment with naloxone might be indicated. Therefore, the patient should be monitored closely for at least 48 hours in order to detect possible CNS depression.

1.3.1.5 Pharmacological properties

1.3.1.5.1 Pharmacodynamic properties

Pharmacotherapeutic Group: Antipropulsives; ATC code: A07DA03

Loperamide binds to the opiate receptor in the gut wall, reducing propulsive peristalsis, increasing intestinal transit time and enhancing resorption of water and electrolytes. Loperamide increases the tone of the anal sphincter, which helps reduce faecal incontinence and urgency.

In a double blind randomised clinical trial in 56 patients with acute diarrhoea receiving loperamide, onset of antidiarrhoeal action was observed within one hour following a single 4 mg dose. Clinical comparisons with other antidiarrhoeal drugs confirmed this exceptionally rapid onset of action of loperamide.

1.3.1.5.2 Pharmacokinetic properties

Absorption: Most ingested loperamide is absorbed from the gut, but as a result of significant first pass metabolism, systemic bioavailability is only approximately 0.3%.

Distribution: Studies on distribution in rats show a high affinity for the gut wall with a preference for binding to receptors of the longitudinal muscle layer. The plasma protein binding of loperamide is 95%, mainly to albumin. Non-clinical data have shown that loperamide is a P-glycoprotein substrate.

Metabolism: loperamide is almost completely extracted by the liver, where it is predominantly metabolized, conjugated and excreted via the bile. Oxidative N-demethylation is the main metabolic pathway for loperamide, and is mediated mainly through CYP3A4 and CYP2C8. Due to this very high first pass effect, plasma concentrations of unchanged drug remain extremely low.

Elimination: The half-life of loperamide in man is about 11 hours with a range of 9-14 hours. Excretion of the unchanged loperamide and the metabolites mainly occurs through the faeces.

1.3.1.5.3 Preclinical safety data

Acute and chronic studies on loperamide showed no specific toxicity. Results of *in vivo* and *in vitro* studies carried out indicated that loperamide is not genotoxic. In reproduction studies, very high doses (40 mg/kg/day – 240 times the maximum human use level) loperamide impaired fertility and foetal survival in association with maternal toxicity in rats. Lower doses had no effects on maternal or foetal health and did not affect peri- and post-natal development.

Non-clinical *in vitro* and *in vivo* evaluation of loperamide indicates no significant cardiac electrophysiological effects within its therapeutically relevant concentration range and at significant multiples of this range (up to 47-fold). However, at extremely high concentrations associated with overdoses (see section 4.4), loperamide has cardiac electrophysiological actions consisting of inhibition of potassium (hERG) and sodium currents, and arrhythmias.

1.3.1.6 Pharmaceutical particulars

1.3.1.6.1 List of excipients

Sodium starch glycolate, Microcrystalline cellulose, Colloidal anhydrous silica, Lactose monohydrate (Dried), Magnesium stearate, EHG Capsule Size '2'.

1.3.1.6.2 Incompatibilities

None known

1.3.1.6.3 Shelf life

36 Months

1.3.1.6.4 Special precautions for storage

Store below 30°C in a dry and dark place.

Keep all medicines out of the reach of children.

1.3.1.6.5 Nature and contents of container**Packing:**

Primary packing: 10 Capsules in an ALU-PVC blister.

Secondary packing: 1 Blister is packed in a printed carton along with leaflet.

Tertiary packing: Shrink such 10 printed cartons with shrinkable PVC Sleeves. Such 100 shrinks are packed in a 5 Ply shipper sealed with BOPP tape & strap with strapping roll.

1.3.1.6.6 Special precautions for disposal and other handling

No special requirements. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

1.3.1.7 Applicant / Manufacturer**Applicant**

Applicant name and address	M/s. TALLIS PHARMACEUTICALS COMPANY NIG. LTD. Niger Road,S/Gari, Kano
Contact person's phone number	
Contact person's email	

Manufacturer

Manufacturer name and address	M/s. IMPULSE PHARMA PVT. LTD. J-201, J-202/1 , MIDC Tarapur, Boisar, Dist. Palghar - 401506, Maharashtra State, India.
Contact person's phone number	+91 9673338586
Contact person's email	cmd@kamlagroup.co.in